Detailed narrative
Strategic Milestones and Aortic Arch Leadership
Artivion achieved two significant milestones in Q2 FY26: US FDA PMA approval for its AMDS hybrid prosthesis and the acquisition of Endospan's Nexus Aortic Arch Stent Graft system. These additions, alongside the CIVO product, establish a "market-leading, three-pronged aortic arch portfolio," positioning the company as the only global provider of a complete suite of aortic arch solutions.
The Nexus system is highlighted as a platform technology with three additional PMA programs in development, expected to further solidify market leadership.
AMDS PMA Impact and Commercial Momentum
The AMDS PMA approval in late June is anticipated to significantly accelerate new account conversion and set sales by eliminating the need for lengthy IRB review processes. Management reported improved AMDS set sales and strong implant trends in Q2 compared to Q1, with further acceleration expected in the second half of the year as initial stocking investment barriers diminish.
The company has also refined its messaging around reimbursement and the clinical benefits of the PMA-approved technology.
ONIX and Stent Graft Performance
Stent Graft revenues demonstrated strong performance, accelerating to 12% constant currency growth in Q2, despite facing tougher year-over-year comparisons. ONIX revenues grew 18% on a constant currency basis, driven by global market share gains and compelling clinical data. This data supports the use of mechanical valves over bioprosthetic valves in younger patients (under 65), contributing to ONIX's market expansion.
Additionally, recent 12-year outcome data for the ROS procedure, published in JAK, reinforced the Sinegraph pulmonary valve's strong clinical profile and market leadership.
Nexus Integration and 2027 Outlook
The Endospan acquisition was completed ahead of schedule, with integration progressing smoothly due to a long-standing partnership. Through 2026, the company will focus on building inventory, securing value analysis committee approvals, and augmenting its U.S. sales team for Nexus. A full U.S. commercial launch is targeted for January 2027.
The Nexus opportunity is concentrated in approximately 150 centers, allowing for a focused commercial strategy with a small, dedicated vascular sales team working in conjunction with the existing cardiac team.
Pipeline and Future Growth Drivers
Progress continues on the Artisan Clinical Trial for the CIVO LSA product, with 30 patients enrolled out of a target of 132. Enrollment completion is expected by mid-2027, with FDA approval anticipated in 2029, which would unlock an incremental $80 million annual U.S. market opportunity.
Artivion identified four primary U.S. aortic growth platforms—AMDS PMA, ONIX heart valves, Nexus, and the Artisan IDE trial—collectively representing an estimated $430 million in annual U.S. market opportunity.
Financial Performance and Cash Flow Dynamics
Total constant currency revenue reached $125.8 million, up 9%, and adjusted EBITDA grew 7% to $26.4 million. However, the adjusted EBITDA margin saw a 90 basis point decrease to 21%, primarily due to increased R&D investments, including those related to Nexus.
Free cash flow was negative $12 million in Q2, significantly impacted by $1.5 million in Endospan diligence/integration expenses and a $10.2 million payment for transaction bonuses. Management expects free cash flow to be meaningfully positive in 2027 due to EBITDA growth, lower capital expenditures, and non-recurring📎 Endospan expenses.